Zook Anthony P. 4

What Happened

• Anthony P. Zook, CEO of Neogenomics (NEO), had 140,498 restricted stock units (RSUs) convert into common stock on April 1, 2026 (reported on Form 4 filed Apr 3, 2026). Per the filing the conversion/issuance shows $0.00 per share (typical for vested RSUs). To cover tax withholding, 45,453 shares were surrendered, leaving a net increase of approximately 95,045 shares to Mr. Zook’s holdings. The filing also reports a related derivative entry for 140,498 shares (reflecting the conversion/settlement of the derivative award).

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (timely under Section 16 rules).
• Primary entries: 140,498 shares acquired via conversion of derivative/RSUs (code M); 45,453 shares disposed for tax withholding (code F). All reported prices shown as $0.00 (vesting/conversion and share-withholding, not open-market trades).
• Net shares received (approx.): 140,498 acquired − 45,453 withheld = ~95,045 shares added.
• Footnotes: RSUs and stock options were granted on April 1, 2025 (421,496 RSUs and 729,927 options vesting ratably over three years) and additional awards granted March 1, 2026. Some options are premium-price grants (exercise price above market as described in footnotes).
• No indication of a 10b5-1 plan or late filing in this report.

Context

• This was not an open-market purchase or sale. The primary event is vesting/conversion of RSUs (a compensation award) and routine share withholding to satisfy tax obligations. Such tax-withholding dispositions are common and do not necessarily signal the insider’s view of the company’s stock price.
• For retail investors: purchases (open-market buys) often carry clearer bullish signals than routine vesting/tax-withholding transactions; treat this as compensation-related activity rather than a directional trade.